Cerevel Therapeutics Holdings (STU:673) 3-Year Book Growth Rate : 7.10% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cerevel Therapeutics Holdings 3-Year Book Growth Rate?

Cerevel Therapeutics Holdings's Book Value per Share for the quarter that ended in Mar. 2024 was €2.86.

During the past 12 months, Cerevel Therapeutics Holdings's average Book Value per Share Growth Rate was 12.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was 7.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 5 years, the highest 3-Year average Book Value per Share Growth Rate of Cerevel Therapeutics Holdings was 75.90% per year. The lowest was 7.10% per year. And the median was 41.50% per year.

Competitive Comparison of Cerevel Therapeutics Holdings's 3-Year Book Growth Rate

For the Biotechnology subindustry, Cerevel Therapeutics Holdings's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cerevel Therapeutics Holdings's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cerevel Therapeutics Holdings's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Cerevel Therapeutics Holdings's 3-Year Book Growth Rate falls into.

Cerevel Therapeutics Holdings 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Cerevel Therapeutics Holdings (STU:673) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Cerevel Therapeutics Holdings 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerevel Therapeutics Holdings (STU:673) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

CERE:USA

Address

222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141

Website

https://www.cerevel.com

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Cerevel Therapeutics Holdings (STU:673) Headlines

No Headlines